Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil adjunct to sevoflurane in ECT
NCT02271555Phase 4Unknown
- Sponsor
- Inonu University
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remifentanil in major depressive disorder (MDD) (2 arms), sponsored by Inonu University. Primary endpoint: Heart Rate after ECT at 20 minute. Status: unknown.
02
Drugs
remifentanil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02271555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271555.